United States · FDA National Drug Code directory
Orilissa
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0074-0039_07f98869-6203-4e8c-b576-2ba8f0a159d7
- Product NDC
- 0074-0039
- Form
- TABLET, FILM COATED
- Composition / generic term
- Elagolix
- Labeler
- AbbVie Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20180723
- Source listing expiry
- 20271231
Source-listed ingredients
- ELAGOLIX SODIUM — 200 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 BLISTER PACK in 1 CARTON (0074-0039-14) / 14 TABLET, FILM COATED in 1 BLISTER PACK · 0074-0039-14
- 4 BLISTER PACK in 1 CARTON (0074-0039-56) / 14 TABLET, FILM COATED in 1 BLISTER PACK · 0074-0039-56
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →